Skip to main content
. 2023 Jan 24;8(2):e164608. doi: 10.1172/jci.insight.164608

Figure 1. IGHMBP2 and ABT1 coimmunoprecipitate.

Figure 1

(A) IGHMBP2 and ABT1 coimmunoprecipitation using anti-IGHMBP2 antibodies for Western blot. Lane 1 shows A/G beads alone, lane 2 shows A/G beads of ABT1 preclear lysate, lane 3 shows A/G beads of IGHMBP2 + ABT1 preclear lysate, lane 4 shows ABT1 lysate IP with anti-GST antibodies, lane 5 shows IGHMBP2 + ABT1 IP with anti-His antibodies, lane 6 shows IGHMBP2 + ABT1 IP with anti-IGHMBP2 antibodies, lane 7 shows protein marker, lane 8 shows IGHMBP2 + ABT1 IP with anti-ABT1 antibodies, lane 9 shows IGHMBP2 + ABT1 IP with anti-GST antibodies, and lane 10 shows IGHMBP2 + ABT1 IP with IP serum (1:20 dilution) (negative control). (B) IGHMBP2 and ABT1 coimmunoprecipitation using anti-ABT1 antibodies for Western blot. Lane 1 shows protein marker, lane 2 shows A/G beads alone, lane 3 shows A/G beads of ABT1 preclear lysate, lane 4 shows A/G beads of IGHMBP2 + ABT1 preclear lysate, lane 5 shows ABT1 lysate IP with anti-GST antibodies, lane 6 shows IGHMBP2 + ABT1 IP with anti-His antibodies, lane 7 shows IGHMBP2 + ABT1 IP with anti-IGHMBP2 antibodies, lane 8 shows IGHMBP2 + ABT1 IP with anti-GST antibodies, lane 9 shows IGHMBP2 + ABT1 IP with anti-ABT1 antibodies, and lane 10 shows IGHMBP2 + ABT1 IP with IP serum (1:20 dilution) (negative control). ABT1, 31 kDa ABT1 + ~26 kDa GST; IGHMBP2, 110 kDa IGHMBP2 + ~14 kDa thioredoxin–6× His.